Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer

20260 citationsJournal Articlegreen Open Access

Authors

Yashasvini Sampathkumar · Memorial Sloan Kettering Cancer Center

Ziad Zakaria · Memorial Sloan Kettering Cancer Center

Kelli O’Connell · Memorial Sloan Kettering Cancer Center

Jenna Bhimani · Memorial Sloan Kettering Cancer Center

V. S. Blinder · Memorial Sloan Kettering Cancer Center

Rachael Burganowski · Kaiser Permanente Washington Health Research Institute

Isaac J. Ergas

Abstract

Clinician- and facility-level factors were associated with chemotherapy dose reductions. Practice-level changes, such as increasing breast cancer patient volumes and practice size, may support optimal dosing practices.

Topics & Keywords

Breast Cancer Treatment Studies Global Cancer Incidence and Screening Neutropenia and Cancer Infections

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

DOI: 10.1093/jnci/djag063

Field-Weighted Citation Impact: 0.00